20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The Medical Genetics Laboratory of the Tor Vergata University-Hospital supports the projects of BIOSCIENCE GENOMICS, particularly in Clinical Germline Analysis according to genetic counselling by germline analysis from the peripheral blood sample and through comparison to somatic sequence to identify deleterious or likely deleterious mutations in tumour predisposing-genes according to the “ACMG list”. Besides the Rome Laboratory, the company owns another genomic platform inside the San Raffaele Hospital in Milan (ranked the first Italian Hospital in terms of quality), with which it recounts years of a strong partnership. With the Center for Omics Sciences – the San Raffaele Scientific Institute and his bioinformatics group, BIOSCIENCE GENOMICS will first analyze raw data from all the sequencing performed during the project using the in-house pipeline. Once big, raw data are transformed into matrices, we will proceed to integrate these datasets among themselves and with clinical data integration. Since 2018, BIOSCIENCE GENOMICS has maintained a scientific and operational partnership with the University Hospital of Basel, and therefore all molecular pathology activities can benefit from their support. Prof. Dr. Luigi Tornillo – Basel University – is a highly experienced molecular pathologist and has been collaborating regularly with BIOSCIENCE GENOMICS since 2018 in interpreting all the reports that the company issues as a result of sequencing tests on cancer and genomic instability driver genes. Daniele Generali, MBChB, MA DPhil, FRCS, MD, DSc Director of the Cancer Unit Hospital of Cremona (IT) and Professor at the Medical Oncology University of Trieste (IT), has excellent experience in the management of cancer patients based on a molecular pathologist diagnosis and supports the project in the management of patients belonging to the 4th subgroup (colon cancer 1° stage).
The development of AI-based platforms, including Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP), for advanced data analysis will be supported by the Physics Dept. of the University of Pisa (IT) and its eco-system (National Research Council, National Institute for Nuclear Physics, the Italian Space Agency, the Scuola Normale Superiore and the Scuola Superiore Sant’Anna in Pisa). Genomedics srl Firenze (IT) will support the implementation of the Artificial Intelligence (AI) techniques with the Generalized Additive Model 2 (GA2M), which has shown significant potential in predicting solid cancers. A GA2M could model the relationship between risk factors (like genetic mutations and environmental exposures) and the probability of developing solid cancer, capturing both individual effects of these variables and their interaction effects. The clinical trial protocol will be developed by a multidisciplinary team and the principal investigators of the clinical trial are Prof. Fabio Pace – Univ. of Milan – Head of Gastroenterology of Seriate Hospital (IT), Prof. Sandro Ardizzone – Head of Gastroenterology of Fatebenebratelli Milan (IT), Dr. Franco Radaelli, Head of Gastroenterology of Valduce Como Hospital (IT), Dr. Gianpiero Manes Head of Gastroenterology of Rho Milan Hospital (IT). The co-investigators for genomic instability are Prof. Michela Biancolella (University-Hospital Tor Vergata Rome) and Prof. Terracciano (Humanitas University Milan); for the immune system, chronic inflammation, and mitochondrial toxicity are Prof. Francesca Granucci and Prof. Elena Sacco (University Bicocca Milan-IT); for molecular pathology Prof. Dr. Luigi Tornillo (Univ. Basel), for oncogenomics and bioinformatics Prof. Giovanni Tonon (Centre for Omics Sciences of San Raffaele Scientific Institute- Milan IT). The company has partnered with the scientific society SIMG (Italian Society of General Medicine and Primary Care – which has about 10,000 members). The scientific society trains family medicine doctors and specialists in cancer driver intercept and disseminating scientific content.
